Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Autor:	Khauli R; Naef K. Basile Cancer Institute, Beirut, Lebanon., Ferrigno R; Hospital BP, São Paulo, Brazil., Guimarães G; Hospital BP, São Paulo, Brazil., Bulbulan M; American University of Beirut, Beirut, Lebanon., Uson Junior PLS; Hospital Israelita Albert Einstein, São Paulo, Brazil., Salvajoli B; Instituto do Câncer de São Paulo, São Paulo, Brazil.; Hospital do Coração, São Paulo, Brazil., Palhares DMF; Hospital Sírio Libanês, São Paulo, Brazil., Racy D; Hospital BP, São Paulo, Brazil., Gil E; Hospital BP, São Paulo, Brazil., de Arruda FF; Hospital Sírio Libanês, São Paulo, Brazil., Lemos GC; Hospital Israelita Albert Einstein, São Paulo, Brazil., Carvalhal GF; Hospital Moinho de Ventos, Porto Alegre, Brazil., de Carvalho IT; Hospital Israelita Albert Einstein, São Paulo, Brazil., Martins IAF; Hospital BP, São Paulo, Brazil., Gimpel IFP; Clínica Santa María, Providencia, Chile., Salvajoli JV; Instituto do Câncer de São Paulo, São Paulo, Brazil.; Hospital do Coração, São Paulo, Brazil., Chambo JL; Hospital BP, São Paulo, Brazil., Pontes J Jr; Instituto do Câncer de São Paulo, São Paulo, Brazil., Filho LAR; Hospital Sírio Libanês, São Paulo, Brazil., Nogueira L; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Freitas MRP; Centro de Pesquisas Oncológicas de Santa Catarina, Santa Catarina, Brazil., Wroclawski M; Hospital Israelita Albert Einstein, São Paulo, Brazil., Arap MA; Hospital Sírio Libanês, São Paulo, Brazil., Sadi MV; Hospital BP, São Paulo, Brazil., Coelho R; Instituto do Câncer de São Paulo, São Paulo, Brazil., Gadia R; Hospital Sírio Libanês, São Paulo, Brazil., Roja RAL; Universidad de Chile, Santiago, Chile., Hanriot RM; Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Baroni R; Hospital Israelita Albert Einstein, São Paulo, Brazil., Zequi S; Hospital do Câncer AC Camargo, São Paulo, Brazil., Nahas WC; Instituto do Câncer de São Paulo, São Paulo, Brazil., Alfer W Jr; Hospital Israelita Albert Einstein, São Paulo, Brazil., Maluf FC; Hospital BP, São Paulo, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 530-537.
DOI:	10.1200/GO.20.00421
Abstrakt:	Purpose: To generate and present survey results on important issues relevant to treatment and follow-up of localized and locally advanced, high-risk prostate cancer (PCa) focusing on developing countries. Methods: A panel of 99 PCa experts developed more than 300 survey questions of which 67 questions concern the main areas of interest of this article: treatment and follow-up of localized and locally advanced, high-risk PCa in developing countries. A larger panel of 99 international multidisciplinary cancer experts voted on these questions to create the recommendations for treatment and follow-up of localized and locally advanced, high-risk PCa in areas of limited resources discussed in this article. Results: The panel voted publicly but anonymously on the predefined questions. Each question was deemed consensus if 75% or more of the full panel had selected a particular answer. These answers are based on panelist opinion and not on a literature review or meta-analysis. For questions that refer to an area of limited resources, the recommendations considered cost-effectiveness as well as the possible therapies with easier and greater access. Each question had five to seven relevant answers including two nonanswers. Results were tabulated in real time. Conclusion: The voting results and recommendations presented in this article can guide physicians managing localized and locally advanced, high-risk PCa in areas of limited resources. Individual clinical decision making should be supported by available data; however, as guidelines for treatment of localized and locally advanced, high-risk PCa in developing countries have not been defined, this article will serve as a point of reference when confronted with this disease. Competing Interests: Raja KhauliHonoraria: Astellas Pharma, Janssen, Algorithm, Hikma, LillyConsulting or Advisory Role: Astellas Pharma, HikmaSpeakers' Bureau: Algorithm, LillyResearch Funding: Astellas Pharma Leopoldo Alves Ribeiro FilhoConsulting or Advisory Role: FerringSpeakers' Bureau: Zodiac Pharma Lucas NogueiraConsulting or Advisory Role: BayerSpeakers' Bureau: Bayer, Astellas Pharma Marcelo Roberto Pereira FreitasConsulting or Advisory Role: Janssen Oncology, Zodiac PharmaSpeakers' Bureau: Astellas Pharma, Janssen Oncology Rodrigo Antonio Ledezma RojaHonoraria: Ferring, Quanta SystemsConsulting or Advisory Role: Quanta Systems, FerringTravel, Accommodations, Expenses: Quanta Systems Rodrigo de Moraes HanriotSpeakers' Bureau: AstraZeneca, Varian Medical Systems, Bristol Myers Squibb, Takeda, Roche Stenio ZequiConsulting or Advisory Role: Pfizer, Astellas BrazilSpeakers' Bureau: Pfizer, Astellas Pharma, Bayer, Janssen, Astra Zeneca Brazil Fernando Cotait MalufHonoraria: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Sanofi/Aventis, Merck Serono, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Merck Serono, AstraZenecaResearch Funding: Janssen-Cilag, Merck Sharp & DohmeTravel, Accommodations, Expenses: Merck Sharp & Dohme, Bayer Schering PharmaNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu